ATE424469T1 - Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung - Google Patents

Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung

Info

Publication number
ATE424469T1
ATE424469T1 AT05766789T AT05766789T ATE424469T1 AT E424469 T1 ATE424469 T1 AT E424469T1 AT 05766789 T AT05766789 T AT 05766789T AT 05766789 T AT05766789 T AT 05766789T AT E424469 T1 ATE424469 T1 AT E424469T1
Authority
AT
Austria
Prior art keywords
disorder
gene
autism
diagnosis
prevention
Prior art date
Application number
AT05766789T
Other languages
English (en)
Inventor
Anne Philippi
Francis Rousseau
Peter Brooks
Joerg Hager
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of ATE424469T1 publication Critical patent/ATE424469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05766789T 2004-07-01 2005-06-30 Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung ATE424469T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58413204P 2004-07-01 2004-07-01

Publications (1)

Publication Number Publication Date
ATE424469T1 true ATE424469T1 (de) 2009-03-15

Family

ID=34982198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05766789T ATE424469T1 (de) 2004-07-01 2005-06-30 Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung

Country Status (10)

Country Link
US (2) US20080193464A1 (de)
EP (1) EP1761650B1 (de)
JP (1) JP2008504838A (de)
AT (1) ATE424469T1 (de)
AU (1) AU2005258841B2 (de)
CA (1) CA2571370A1 (de)
DE (1) DE602005013080D1 (de)
DK (1) DK1761650T3 (de)
IL (1) IL179831A (de)
WO (1) WO2006003523A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006017045D1 (de) * 2005-03-24 2010-11-04 Integragen Sa Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
WO2008126932A2 (en) * 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
US20100248235A1 (en) * 2007-10-04 2010-09-30 Scherer Stephen W Biomarkers for autism spectrum disorders
US20120201908A1 (en) * 2009-08-19 2012-08-09 Lunera Equities, Lllp Method of treating bipolar disorder or depression using an antiestrogen
JP6591748B2 (ja) * 2011-10-31 2019-10-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 自閉症の処置のための方法および組成物
EP2724721A1 (de) * 2012-10-26 2014-04-30 Matentzoglu, Konstantin Zusammensetzung zur Verwendung bei der Behandlung des Angelman-Syndroms und/oder von autistischen Spektrumsstörungen, die Verwendung einer solchen Zusammensetzung und ein Verfahren zur Herstellung eines Medikamentes für die Behandlung des Angelman-Syndroms und/oder von autistischen Spektrumsstörungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2004037991A2 (en) * 2002-10-23 2004-05-06 Exelixis, Inc. Prkcb1 as modifier of branching morphogenesis and methods of use

Also Published As

Publication number Publication date
DE602005013080D1 (de) 2009-04-16
US20080193464A1 (en) 2008-08-14
WO2006003523A2 (en) 2006-01-12
US20100240539A1 (en) 2010-09-23
IL179831A0 (en) 2007-05-15
EP1761650A2 (de) 2007-03-14
WO2006003523A3 (en) 2006-05-18
AU2005258841A1 (en) 2006-01-12
DK1761650T3 (da) 2009-06-29
IL179831A (en) 2011-06-30
EP1761650B1 (de) 2009-03-04
AU2005258841B2 (en) 2010-07-01
JP2008504838A (ja) 2008-02-21
CA2571370A1 (en) 2006-01-12
WO2006003523A8 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
Jiang et al. Transcriptomic and functional studies reveal undermined chemotactic and angiostimulatory properties of aged microglia during stroke recovery
MY164376A (en) Phosphospecific antibodies recognizing tau
Kálmán et al. Human dermal fibroblasts in psychiatry research
WO2014009733A3 (en) Therapeutic targets for alzheimer's disease
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
ATE431855T1 (de) Menschliches autismus-suszeptibilitätsgen und verwendungen davon
Ben‐Reuven et al. Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
ATE424469T1 (de) Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
ATE382101T1 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen
Rikos et al. TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
WO2006090288A3 (en) Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof
WO2010121834A3 (en) Irak kinase family as novel target and biomarker for alzheimer
WO2001020025A3 (en) Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications
Edgünlü et al. A study of the impact of death receptor 4 (DR4) gene polymorphisms in Alzheimer’s disease
WO2006003526A3 (en) Human autism susceptibility gene encoding otoa and uses thereof
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
JP2017500306A5 (de)
Mohammad Jafari et al. Can Cerebellar Neurodevelopmental Disorders Affect Behavioral Disorders or Vice Versa?
DE602005016676D1 (de) Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas-suszeptibilitätssgen und dessen verwendung
PH12013501724A1 (en) Glycine transporter-inhibiting substances

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1761650

Country of ref document: EP